125 related articles for article (PubMed ID: 20668479)
1. Medical oncology: Optimizing chemotherapy and radiotherapy for anaplastic glioma.
Morris PG; Lassman AB
Nat Rev Clin Oncol; 2010 Aug; 7(8):428-30. PubMed ID: 20668479
[No Abstract] [Full Text] [Related]
2. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
[TBL] [Abstract][Full Text] [Related]
3. Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected].
DeAngelis LM
J Clin Oncol; 2009 Dec; 27(35):5861-2. PubMed ID: 19901101
[No Abstract] [Full Text] [Related]
4. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M
Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788
[TBL] [Abstract][Full Text] [Related]
5. MGMT Promoter Methylation and Chemotherapy Outcomes in Low-Grade and Anaplastic Gliomas.
Zhao B; Qi H; Ma W
JAMA Oncol; 2023 Dec; 9(12):1734-1735. PubMed ID: 37856142
[No Abstract] [Full Text] [Related]
6. MGMT promoter methylation is associated with patient age and 1p/19q status in IDH-mutant gliomas.
Horbinski C; McCortney K; Stupp R
Neuro Oncol; 2021 May; 23(5):858-860. PubMed ID: 33830235
[No Abstract] [Full Text] [Related]
7. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG
Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718
[TBL] [Abstract][Full Text] [Related]
8. MGMT Promoter Methylation and Chemotherapy Outcomes in Low-Grade and Anaplastic Gliomas-Reply.
Kinslow CJ; Cheng SK; Wang TJC
JAMA Oncol; 2023 Dec; 9(12):1735-1736. PubMed ID: 37856114
[No Abstract] [Full Text] [Related]
9. [Chemotherapy for brain tumors in adult patients].
Weller M
Nervenarzt; 2008 Feb; 79(2):231-41. PubMed ID: 18253773
[TBL] [Abstract][Full Text] [Related]
10. Clinical and Molecular Recursive Partitioning Analysis of High-grade Glioma Treated With IMRT.
Sutera P; Kalash R; Flickinger J; Engh J; Heron DE
Am J Clin Oncol; 2019 Jan; 42(1):27-35. PubMed ID: 29912004
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide and MGMT forever?
Weller M
Neuro Oncol; 2010 Mar; 12(3):219-20. PubMed ID: 20167809
[No Abstract] [Full Text] [Related]
12. Editorial for "Apparent Diffusion Coefficient as Imaging Biomarker for Identifying IDH Mutation, 1p19q Codeletion, and MGMT Promoter Methylation Status in Patients With Glioma".
Salihoğlu AK; Booth TC
J Magn Reson Imaging; 2023 Sep; 58(3):739-740. PubMed ID: 36594487
[No Abstract] [Full Text] [Related]
13. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of molecular biomarkers in gliomas.
Siegal T
J Clin Neurosci; 2015 Mar; 22(3):437-44. PubMed ID: 25533211
[TBL] [Abstract][Full Text] [Related]
15. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
Chamberlain MC
Neurology; 2014 Jun; 82(23):2147-8. PubMed ID: 24912510
[No Abstract] [Full Text] [Related]
16. Progress in the application of molecular biomarkers in gliomas.
Wang J; Su HK; Zhao HF; Chen ZP; To SS
Biochem Biophys Res Commun; 2015 Sep; 465(1):1-4. PubMed ID: 26253473
[TBL] [Abstract][Full Text] [Related]
17. MGMT promoter methylation in pediatric high-grade gliomas.
Fassan M; Tassone E; Onisto M; Perilongo G; D'Avella D; Gardiman MP
Childs Nerv Syst; 2011 Jan; 27(1):7-8. PubMed ID: 21052697
[No Abstract] [Full Text] [Related]
18. Incidence of biomarkers in high-grade gliomas and their impact on survival in a diverse SouthEast Asian cohort - a population-based study.
Ang SYL; Lee L; See AAQ; Ang TY; Ang BT; King NKK
BMC Cancer; 2020 Jan; 20(1):79. PubMed ID: 32005184
[TBL] [Abstract][Full Text] [Related]
19. The association between
Okita Y; Shofuda T; Kanematsu D; Yoshioka E; Kodama Y; Mano M; Kinoshita M; Nonaka M; Fujinaka T; Kanemura Y
Clin Radiol; 2020 Aug; 75(8):622-628. PubMed ID: 32321646
[TBL] [Abstract][Full Text] [Related]
20. Updates in prognostic markers for gliomas.
Aquilanti E; Miller J; Santagata S; Cahill DP; Brastianos PK
Neuro Oncol; 2018 Nov; 20(suppl_7):vii17-vii26. PubMed ID: 30412261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
